Table 2.
Effect of BGP-15 treatment on echocardiographic parameters.
| WKY (n = 7) | SHR-Baseline (n = 7) | SHR-C (n = 7) | SHR-B (n = 7) | |
|---|---|---|---|---|
| Mean ± SEM | Mean ± SEM | Mean ± SEM | Mean ± SEM | |
| Septum | 1.93 ± 0.03 | 2.29 ± 0.07∗∗ | 2.32 ± 0.07∗∗ | 2.09 ± 0.08∗,§ |
| PW | 1.90 ± 0.04 | 2.06 ± 0.06∗ | 1.97 ± 0.08∗ | 1.81 ± 0.07§ |
| LVIDd (mm) | 7.61 ± 0.14 | 7.75 ± 0.15 | 8.55 ± 0.23∗∗,## | 8.31 ± 0.18∗∗ |
| LVIDs (mm) | 4.54 ± 0.13 | 4.60 ± 0.21 | 5.87 ± 0.31∗∗,## | 5.19 ± 0.32§ |
| LVEDV (μl) | 310.25 ± 12.85 | 323.07 ± 14.59 | 402.40 ± 24.76∗∗,## | 377.19 ± 17.37∗∗ |
| LVESV (μl) | 96.01 ± 6.85 | 101.51 ± 12.27 | 175.52 ± 22.46∗∗,## | 137.23 ± 16.46∗∗,§ |
| LV mass (mg) | 1029.81 ± 43.84 | 1384.42 ± 40.69∗∗ | 1587.38 ± 106.36∗∗,# | 1321.44 ± 75.58∗,§ |
| EF% | 70.48 ± 1.12 | 69.59 ± 2.41 | 57.21 ± 3.02∗∗,## | 64.30 ± 2.88∗,§ |
| E/A | 1.37 ± 0.07 | 1.70 ± 0.09∗∗ | 2.02 ± 0.06∗∗ | 1.27 ± 0.08§§ |
| E/E' | 30.45 ± 2.00 | 30.32 ± 2.98 | 40.41 ± 2.94∗∗,## | 25.71 ± 3.03§§ |
| BNP (pg/ml) | 302.76 ± 13.76 | 325.19 ± 10.89 | 755.14 ± 33.34∗,# | 352.04 ± 22.50§ |
Septum: thickness of the septum; PW: thickness of the posterior wall; LVIDd: left ventricular (LV) inner diameter end-diastolic; LVIDs: LV inner diameter end-systolic; LVEDV: LV end-diastolic volume; LVESV: LV end-systolic volume; LV mass: calculated weight of left ventricle; EF: ejection fraction; E: mitral peak velocity of early filling; A: mitral peak velocity of late filling; E': early diastolic mitral annular velocity; A': late diastolic mitral annular velocity; BNP: B type natriuretic peptide. WKY: age-matched normotensive Wistar-Kyoto rats, n = 7; SHR-Baseline: 15-month-old spontaneously hypertensive rats, n = 7; SHR-C: 19-month-old spontaneously hypertensive rats received placebo for 18 weeks, n = 7; SHR-B: 19-month-old spontaneously hypertensive rats received BGP-15 for 18 weeks, n = 7. ∗p < 0.05 vs. WKY, ∗∗p < 0.01 vs. WKY, #p < 0.05 vs. SHR-Baseline, ##p < 0.01 SHR-Baseline, §p < 0.05 vs. SHR-C, §§p < 0.01 vs. SHR-C.